Figure 7.

Patient-derived NB tumoroids are sensitive to CHK1 inhibition and improved in vitro efficacy is observed with the addition of WEE1 inhibition. (A) Dose-response curves of 11q deleted, MYCN wild type NB tumoroids (NB059 and AMC772) following 72-hour treatment with prexasertib only (prex, solid line) or in combination with 16 nM adavosertib (ada, dashed line). (B) Dose-response curves of 11q wild type NB tumoroids with MYCN amplification (NB129, orange) and without MYCN amplification (NB139, red) following prexasertib treatment (prex, solid line) or prexasertib in combination with 16 nM of adavosertib (ada, dashed line). All curves represent the average of replicates (n=2) where error bars indicate the standard error of the mean (SEM). (C) Bliss independence heatmaps for NB tumoroids following combination treatment with 0.03-10 µM prexasertib and adavosertib.